Tempest data provide POC for PPAR alpha’s role in cancer

New data from immuno-oncology company Tempest Therapeutics Inc. (San Francisco, Calif.) provide preclinical proof of concept that the established cardiovascular disease target PPARα also plays a role in cancer.

At last week's Society for Cancer Immunotherapy in Cancer meeting in Washington, the company showed its lead product, PPARα antagonist TPST-1120, decreased tumor growth in mice as a single agent and in combination with an anti-PD-1 antibody or chemotherapy...